Skip to main content
. Author manuscript; available in PMC: 2014 Sep 2.
Published in final edited form as: JAMA Ophthalmol. 2014 Aug 1;132(8):915–921. doi: 10.1001/jamaophthalmol.2014.1019

Table 3.

Multivariate Analysis of Baseline Factors Associated With Sustained Visual Acuity Loss

Factor Patients at Risk, No.a Sustained Visual Acuity Loss, No. (%) Adjusted Odds Ratio (95% CI) P Value
Baseline nonfoveal geographic atrophy
None or questionable 959 51 (5.3) 1 [Reference] .006
Present 70 10 (14.3) 2.86 (1.35–6.08)
Baseline area of CNV (disc area)
 ≤1 417 14 (3.4) 1 [Reference] .007
 >1-≤2 203 10 (4.9) 1.63 (0.70–3.76)
 >2-≤4 190 14 (7.4) 2.44 (1.13–5.28)
 >4 100 11 (11.0) 3.91 (1.70–9.03)
 Unknown 119 12 (10.1) 3.30 (1.47–7.44)
Drug group
 Ranibizumab 528 24 (4.6) 1 [Reference] .03
 Bevacizumab 501 37 (7.4) 1.83 (1.07–3.14)
Regimen group
 Monthly always 262 11 (4.2) 1 [Reference] .24
 Monthly in year 1, as needed in year 2 252 20 (7.9) 1.92 (0.89–4.15)
 As needed always 515 30 (5.8) 1.37 (0.67–2.81)

Abbreviation: CNV, choroidal neovascularization.

a

One patient was excluded for an unknown status on baseline nonfoveal geographic atrophy.